Work

72P Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1

Year: 2026

Type: article

Abstract: Previous report of EMPOWER-Lung 1 showed significant and durable survival benefits and acceptable safety profile of 1L cemiplimab monotherapy vs chemotherapy (chemo) for advanced NSCLC with PD-L1 ≥50% of tumour cells and no EGFR, ALK, or ROS1 aberrations. We now report 6-year (y) follow-up outcomes, offering a robust evaluation of long-term efficacy and safety of cemiplimab. We also report results from patients who completed a full course of cemiplimab treatment.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106379

Authors: M. Gogishvili, S. Kilickap, A. Baramidze, A. Sezer, M. Ozguroglu, M. Gumus, I. Bondarenko, M. Nechaeva, M. Schenker, I. Cicin, G.F. Ho, Y. Kulyaba, Z.I. Kasimova, R.I. Scheusan, M.C. Garassino, Y. Li, X. Jia, M. Kaul, S. Chua, H. Magnan

Institutions: Istinye University, Georgian National Museum, Başkent University, Istanbul University-Cerrahpaşa, Istanbul University, Istanbul Medeniyet University, Dnipro State Medical University, Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser, University of Malaya, National Institute of Emergency Medicine "Pirogov", University of Chicago, Regeneron (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

Funders: Sanofi, Regeneron Pharmaceuticals

OpenAlex ID: W7138385488

FWCI:

Cites:

Cited by:

Related to: